Literature DB >> 6849768

Characterization of chloroquine plasma protein binding in man.

O Walker, D J Birkett, G Alván, L L Gustafsson, F Sjöqvist.   

Abstract

Chloroquine protein binding was determined by equilibrium dialysis of purified plasma proteins and plasma samples from 20 healthy subjects and 14 patients with rheumatoid arthritis. The mean binding was 61 +/- 9% in plasma from healthy subjects (range 46-74%) and 64 +/- 7% in plasma from rheumatoid arthritis patients (range 55-79%). Albumin and alpha 1-acid glycoprotein at physiological concentrations bound chloroquine to an approximately equal extent. Protein binding is unlikely to be an important determinant of chloroquine pharmacokinetics or response.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849768      PMCID: PMC1427768          DOI: 10.1111/j.1365-2125.1983.tb01513.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  3 in total

1.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

2.  Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.

Authors:  M Ehrnebo; S Agurell; B Jalling; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

3.  The binding of chloroquine to normal and Kwashiorkor serum.

Authors:  N Buchanan; L A Van der Walt
Journal:  Am J Trop Med Hyg       Date:  1977-09       Impact factor: 2.345

  3 in total
  25 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Drug treatment and prevention of malaria.

Authors:  N J White
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

4.  Excretion of hydroxychloroquine in human milk.

Authors:  R L Nation; L P Hackett; L J Dusci; K F Ilett
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

6.  Protein binding of chloroquine enantiomers and desethylchloroquine.

Authors:  D Ofori-Adjei; O Ericsson; B Lindström; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

7.  Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites.

Authors:  A J McLachlan; D J Cutler; S E Tett
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  The protein binding of timegadine determined by equilibrium dialysis.

Authors:  S George; A McBurney; J Ward
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

9.  Single dose disposition of chloroquine in kwashiorkor and normal children--evidence for decreased absorption in kwashiorkor.

Authors:  O Walker; A H Dawodu; L A Salako; G Alván; A O Johnson
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

10.  Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis.

Authors:  P Augustijns; P Geusens; N Verbeke
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.